[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20181890T1 - Derivati dolastatina 10 i auristatina - Google Patents

Derivati dolastatina 10 i auristatina

Info

Publication number
HRP20181890T1
HRP20181890T1 HRP20181890TT HRP20181890T HRP20181890T1 HR P20181890 T1 HRP20181890 T1 HR P20181890T1 HR P20181890T T HRP20181890T T HR P20181890TT HR P20181890 T HRP20181890 T HR P20181890T HR P20181890 T1 HRP20181890 T1 HR P20181890T1
Authority
HR
Croatia
Prior art keywords
auristatins
dolastatin
derivatives
Prior art date
Application number
HRP20181890TT
Other languages
English (en)
Inventor
Michel Perez
Ian RILATT
Marie Lamothe
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of HRP20181890T1 publication Critical patent/HRP20181890T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20181890TT 2013-04-25 2018-11-14 Derivati dolastatina 10 i auristatina HRP20181890T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353793A FR3005051A1 (fr) 2013-04-25 2013-04-25 Derives de la dolastatine 10 et d'auristatines
EP14719328.8A EP2989086B1 (en) 2013-04-25 2014-04-25 Derivatives of dolastatin 10 and auristatins
PCT/EP2014/058422 WO2014174060A1 (en) 2013-04-25 2014-04-25 Derivatives of dolastatin 10 and auristatins

Publications (1)

Publication Number Publication Date
HRP20181890T1 true HRP20181890T1 (hr) 2019-01-11

Family

ID=48782433

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171977TT HRP20171977T1 (hr) 2013-04-25 2017-12-20 Derivati dolastatina 10 i auristatina
HRP20181890TT HRP20181890T1 (hr) 2013-04-25 2018-11-14 Derivati dolastatina 10 i auristatina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20171977TT HRP20171977T1 (hr) 2013-04-25 2017-12-20 Derivati dolastatina 10 i auristatina

Country Status (32)

Country Link
US (7) US20160083420A1 (hr)
EP (4) EP2989088B1 (hr)
JP (3) JP6017728B2 (hr)
KR (4) KR102389167B1 (hr)
CN (3) CN105143199A (hr)
AU (3) AU2014259431B2 (hr)
BR (3) BR112015026410B1 (hr)
CA (4) CA3130994A1 (hr)
CY (2) CY1119677T1 (hr)
DK (3) DK3388427T3 (hr)
ES (3) ES2908224T3 (hr)
FR (1) FR3005051A1 (hr)
HK (2) HK1215580A1 (hr)
HR (2) HRP20171977T1 (hr)
HU (3) HUE058167T2 (hr)
IL (1) IL242184A (hr)
LT (2) LT2989088T (hr)
MA (1) MA38583B1 (hr)
MX (3) MX345126B (hr)
MY (1) MY177702A (hr)
NO (1) NO2989088T3 (hr)
NZ (1) NZ714203A (hr)
PL (3) PL3388427T3 (hr)
PT (2) PT2989086T (hr)
RS (2) RS56717B1 (hr)
RU (3) RU2015147447A (hr)
SA (1) SA515370043B1 (hr)
SI (2) SI2989088T1 (hr)
TN (2) TN2015000445A1 (hr)
UA (1) UA115806C2 (hr)
WO (3) WO2014174064A1 (hr)
ZA (1) ZA201508545B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
RS59799B1 (sr) * 2014-04-25 2020-02-28 Pf Medicament Konjugat antitelo - lek i njegova upotreba u lečenju kancera
KR101795984B1 (ko) 2014-04-25 2017-11-10 피에르 파브르 메디카먼트 Igf-1r 항체-약물-결합체 및 암의 치료를 위한 그의 용도
WO2016001485A1 (en) 2014-06-30 2016-01-07 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
TWI732826B (zh) * 2016-02-26 2021-07-11 大陸商江蘇恆瑞醫藥股份有限公司 一種新毒素及其中間體的製備方法
PT3438118T (pt) * 2016-03-29 2023-06-07 Toray Industries Derivado de peptídeo e utilização deste
CN105968038A (zh) * 2016-05-09 2016-09-28 湖北华世通生物医药科技有限公司 二肽类化合物的盐酸盐及其制备方法
CN106432318A (zh) * 2016-08-18 2017-02-22 重庆大学 一种芳炔前体的设计，合成，及在合成多取代芳烃的应用
CN107325033A (zh) * 2017-06-23 2017-11-07 华东师范大学 一种高立体选择性合成海兔毒素Dap片段的方法
EP3717503B1 (en) * 2017-11-30 2023-11-08 LadRx Corporation Albumin-binding prodrugs of auristatin e derivatives
MX2021003295A (es) 2018-09-27 2021-07-16 Pf Medicament Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
CN110724337B (zh) * 2019-10-16 2022-04-05 江苏德威新材料股份有限公司 一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024213080A1 (zh) * 2023-04-12 2024-10-17 荣昌生物制药(烟台)股份有限公司 一种甲基奥瑞他汀e化合物的制备及纯化方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3469580B2 (ja) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP3498289A1 (en) * 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
RU2556129C2 (ru) * 2008-04-11 2015-07-10 Сиэтл Дженетикс, Инк. Диагностика и лечение злокачественных опухолей поджелудочной железы, яичников и других злокачественных опухолей
EP2403524A4 (en) * 2009-03-06 2012-09-26 Agensys Inc CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12
EP2579887B1 (de) * 2010-06-10 2014-11-12 Seattle Genetics, Inc. Neue auristatin-derivate und ihre verwendung
US8987209B2 (en) * 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
WO2012059882A2 (en) * 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
ES2543888T3 (es) * 2011-03-16 2015-08-25 Seattle Genetics, Inc. N-carboxialquil-auristatinas y su utilización
EP2699268A2 (de) * 2011-04-21 2014-02-26 Seattle Genetics, Inc. Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
AU2012262560B2 (en) * 2011-05-27 2016-06-09 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
MX345538B (es) * 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
MX363116B (es) * 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
AU2013277169B2 (en) * 2012-06-19 2017-02-02 Ambrx, Inc. Anti-CD70 antibody drug conjugates
EP2934596A1 (en) * 2012-12-21 2015-10-28 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
RS59799B1 (sr) * 2014-04-25 2020-02-28 Pf Medicament Konjugat antitelo - lek i njegova upotreba u lečenju kancera

Also Published As

Publication number Publication date
CN105143199A (zh) 2015-12-09
AU2014259431B2 (en) 2017-02-02
CA2910178A1 (en) 2014-10-30
US20180222858A1 (en) 2018-08-09
HUE035180T2 (hu) 2018-05-02
WO2014174060A1 (en) 2014-10-30
PT2989086T (pt) 2018-11-29
DK3388427T3 (da) 2022-03-07
CY1119677T1 (el) 2018-04-04
RU2015146957A (ru) 2017-05-31
AU2014259429A1 (en) 2015-11-12
LT2989086T (lt) 2018-11-26
PL3388427T3 (pl) 2022-05-09
KR20160003735A (ko) 2016-01-11
WO2014174064A1 (en) 2014-10-30
KR20160003734A (ko) 2016-01-11
AU2014259427B2 (en) 2018-04-05
WO2014174062A1 (en) 2014-10-30
HRP20171977T1 (hr) 2018-02-09
FR3005051A1 (fr) 2014-10-31
EP2989086A1 (en) 2016-03-02
KR102368136B1 (ko) 2022-02-25
MA38583A1 (fr) 2018-07-31
SI2989088T1 (en) 2018-02-28
ES2654364T3 (es) 2018-02-13
RS56717B1 (sr) 2018-03-30
CA2909126A1 (en) 2014-10-30
US20210107868A1 (en) 2021-04-15
ZA201508545B (en) 2017-07-26
KR20210046871A (ko) 2021-04-28
RU2015149527A (ru) 2017-05-29
CN105377834A (zh) 2016-03-02
JP2016519114A (ja) 2016-06-30
US20160068567A1 (en) 2016-03-10
RU2662951C2 (ru) 2018-07-31
CN105377834B (zh) 2018-04-20
KR20160003003A (ko) 2016-01-08
MX345126B (es) 2017-01-17
MX2015014831A (es) 2016-08-03
EP3388427B1 (en) 2022-01-19
HK1215580A1 (zh) 2016-09-02
EP2989088A1 (en) 2016-03-02
PL2989086T3 (pl) 2019-02-28
HUE040431T2 (hu) 2019-03-28
EP2989086B1 (en) 2018-08-22
RU2015147447A (ru) 2017-05-31
ES2908224T3 (es) 2022-04-28
MX2015014746A (es) 2016-03-04
IL242184A (en) 2017-09-28
JP6606489B2 (ja) 2019-11-13
CN105408318A (zh) 2016-03-16
NZ714203A (en) 2020-05-29
KR101640361B1 (ko) 2016-07-15
US20230002316A1 (en) 2023-01-05
PL2989088T3 (pl) 2018-03-30
NO2989088T3 (hr) 2018-02-24
CA3130994A1 (en) 2014-10-30
BR112015026478A2 (pt) 2017-07-25
KR102389167B1 (ko) 2022-04-20
SI2989086T1 (sl) 2018-12-31
EP2989087A1 (en) 2016-03-02
PT2989088T (pt) 2018-01-03
ES2693368T3 (es) 2018-12-11
RS58161B1 (sr) 2019-03-29
US20160068566A1 (en) 2016-03-10
MA38583B1 (fr) 2018-11-30
US20200010414A1 (en) 2020-01-09
HK1215867A1 (zh) 2016-09-23
BR112015026410B1 (pt) 2022-06-07
CY1120863T1 (el) 2019-12-11
SA515370043B1 (ar) 2018-01-24
MX2015014941A (es) 2016-03-07
BR112015026565A2 (pt) 2017-07-25
EP3388427A1 (en) 2018-10-17
TN2015000445A1 (en) 2017-04-06
JP2016519115A (ja) 2016-06-30
CA2910176C (en) 2021-11-09
HUE058167T2 (hu) 2022-07-28
AU2014259431A1 (en) 2015-12-03
DK2989086T3 (en) 2018-11-12
DK2989088T3 (en) 2017-12-18
AU2014259427A1 (en) 2015-11-19
JP2016520041A (ja) 2016-07-11
MY177702A (en) 2020-09-23
UA115806C2 (uk) 2017-12-26
EP2989088B1 (en) 2017-09-27
JP6017728B2 (ja) 2016-11-02
US20160083420A1 (en) 2016-03-24
TN2015000439A1 (en) 2017-01-03
CA2910176A1 (en) 2014-10-30
BR112015026410A2 (pt) 2017-07-25
LT2989088T (lt) 2018-01-10

Similar Documents

Publication Publication Date Title
HRP20181890T1 (hr) Derivati dolastatina 10 i auristatina
IL273090B (en) Methods and preparations for the treatment of cancer
IL265876A (en) Preparations that include 15-ohepa and methods of using them
HK1258409A1 (zh) 抗cd22抗體-美登木素綴合物及其使用方法
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
HUE050547T2 (hu) Oligoszaccharid konjugátumok és alkalmazási eljárások
TH1501006461A (th) อนุพันธ์ของโดลาสแททิน 10 และออริสแททิน (Derivatives of dolastatin 10 and auristatins)
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same